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Background: Early administration of the antifibrinolytic drug tranexamic acid reduces death from bleeding in trauma and
postpartum haemorrhage. We examined how the effectiveness and safety of antifibrinolytic drugs varies by the baseline
risk of death as a result of bleeding.
Methods: We performed an individual patient-level data meta-analysis of randomised trials including more than 1000
patients that assessed antifibrinolytics in acute severe bleeding. We identified trials performed between January 1, 1946
and July 5, 2018 (PROSPERO, number 42016052155).
Results: Two randomised trials were selected where 28 333 patients received tranexamic acid treatment within 3 h after
the onset of acute bleeding. Baseline characteristics to estimate the risk of death as a result of bleeding were divided into
four categories: Low (0e5%), intermediate (6e10%), high (11e20%), and very high (>20%). Most patients had a low baseline
risk of death as a result of bleeding (23 008 [81%]). Deaths as a result of bleeding occurred in all baseline risk categories
with 240 (1%), 202 (8%), 232 (14%), and 357 (30%) deaths in the low-, intermediate-, high-, and very high-risk categories,
respectively. The effectiveness of tranexamic acid did not vary by baseline risk when given within 3 h after bleeding
onset (P¼0.51 for interaction term). There was no increased risk of vascular occlusive events with tranexamic acid and it
did not vary by baseline risk categories (P¼0.25).
Conclusions: Tranexamic acid appears to be safe and effective regardless of baseline risk of death. Because many deaths
are in patients at low and intermediate risk, tranexamic acid use should not be restricted to the most severely injured or
bleeding patients.
Keywords: antifibrinolytics; bleeding; coagulopathy; mortality; postpartum haemorrhage; traumaEditor’s key points
 This meta-analysis investigated how the effectiveness
and safety of tranexamic acid varies by the baseline risk
of death as a result of acute bleeding.d: 5 October 2019 Accepted: 27 January 2020
he Author(s). Published by Elsevier Ltd on behalf of British Journal of A
commons.org/licenses/by/4.0/).
issions, please email: permissions@elsevier.com The study shows thatmany deaths from bleeding are in
patients at low or intermediate risk.
 The effectiveness of tranexamic acid seems not to vary
by the baseline risk of patients.
 Tranexamic acid should therefore not be limited to the
most severely injured or bleeding patients.naesthesia. This is an open access article under the CC BY license (http://
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Effect of tranexamic acid - 677The Anti-Fibrinolytic Trials Collaboration previously pub-
lished a meta-analysis of individual patient data showing that
early administration of tranexamic acid safely reduces death
from acute severe bleeding.1 When given soon after bleeding
onset, tranexamic acid reduces the relative risk of death as a
result of bleeding by about one-third. Early tranexamic acid
treatment is widely recommended in treatment guidelines for
acute severe bleeding, including postpartum haemorrhage
and major trauma.2e4
Many guidelines, especially those for trauma, focus on the
use of tranexamic acid in severely injured patients with a high
risk of death from bleeding.5,6 Although these patients have
much to gain from tranexamic acid treatment, they are few in
number and many die at the scene.7 Because there are many
more patients with less severe injuries and a lower risk of
death from bleeding, if tranexamic acid was similarly effec-
tive, prompt treatment of these patients could prevent many
deaths. We examined how the effectiveness and safety of
antifibrinolytic drugs vary by the baseline risk of death as a
result of bleeding.Methods
Design and selection criteria
We conducted an individual patient data meta-analysis of
randomised, placebo-controlled trials conducted between
January 1, 1946 and July 5, 2018. Themethods and the selection
criteria were described previously.1 The study protocol was
registered in November 2016 (PROSPERO, number
42016052155).8 Any randomised trial with more than 1000
patients that assessed the effects of antifibrinolytic drugs
(aprotinin, tranexamic acid, aminocaproic acid, and amino-
methylbenzoic acid) in patients with acute bleeding was
eligible for inclusion. We identified trials from a permanent
register of antifibrinolytic trials maintained by the London
School of Hygiene and Tropical Medicine Clinical Trials Unit.
The register is based on searches of MEDLINE, Embase, the
Cochrane Central Register of Controlled Trials,Web of Science,
PubMed, Popline, and the WHO International Clinical Trials
Registry Platform (Supplementary file S1). Three reviewers
(AG-A, KK, F-XA) independently extracted data. We selected
trials recruiting patients with acute bleeding at the time of
randomisation (treatment trials). We excluded patients who
were randomised more than 3 h after bleeding onset, since
previous studies have shown that antifibrinolytics are inef-
fective after this period.We prepared a statistical analysis plan
before searching for trials. Patients and the public were not
involved in the research.Outcome
The primary outcomewas death as a result of bleeding. This is
the most relevant primary outcome given the mechanism of
action of antifibrinolytic drugs. All-cause mortality includes
non-bleeding related deaths, such as sepsis, that should not be
affected by antifibrinolytics. Because these deaths could dilute
the treatment effect, important benefits or harms could be
obscured in all-cause mortality.9 Moreover, because the rela-
tive contributions of non-bleeding deaths will vary between
populations, all-cause mortality is not widely generalisable.
Secondary outcomes were fatal and non-fatal vascular occlu-
sive events (myocardial infarction, stroke, pulmonary embo-
lism, and DVT).Data analysis
We evaluated the quality of included trials by assessing
sequence generation, allocation concealment, blinding, data
completeness, and risk of selective reporting. Analysis was
based on individual patient-level data. We estimated the
baseline risk of death as a result of bleeding separately for each
trial. We used prognostic models to predict the baseline risk
using multivariate logistic regression. We used a previously
published prognostic model for trauma.10 Because there were
no suitable prognostic models for postpartum haemorrhage,
we used the same method to develop a prognostic model for
postpartum haemorrhage. We only used baseline characteris-
tics collected before randomisation as predictors. To improve
the precision of our models, we included all trial participants
from the treatment and placebo groups.11 We included all po-
tential predictors at baseline and adjusted for the use of anti-
fibrinolytic drugs.We included linear and polynomial terms for
continuous variables. We used the backward stepwisemethod
and removed one at a time, variables for which there was no
evidence of association (P-value for the Wald test >0.05). To
estimate the risk at baseline, the coefficient for antifibrinolytic
drugs was constrained at 0 in the equation. We performed
sensitivity analysis that estimated the baseline risk in the pla-
cebo arm and present the results in the supplementary files.
The estimates would be less precise, but may avoid misclassi-
fication from assuming a constant effect of tranexamic acid.
The predicted baseline risk of death as a result of bleeding was
estimated for each trial participant in both treatment groups.
For each prognostic model, we assessed the performance by
estimating discrimination and calibration. Discrimination
represents the ability of themodel to identify a patientwith the
outcome of interest and is evaluated by the concordance sta-
tistic (C-Statistic). Calibration represents the agreement be-
tween predicted and observed risk. On the basis of the
predictedbaseline risk, participantswere assigned tooneof the
four baseline categories of risk of death as a result of bleeding:
0e5% (low); 6e10% (intermediate); 11e20% (high), and >20%
(very high). The categories were chosen because they were
clinically relevant, easy to understand (using a base of 5 or 10),
and consistent with previous studies.12,13
All analyses were done according to the intention-to-treat
principle. We reported continuous variables as mean (stan-
dard deviation) andmedian (inter-quartile range).We reported
categorical variables as numbers and proportions. We plotted
frequency distributions for baseline risk in all participants and
in patients who died from bleeding. We estimated the effect of
antifibrinolytics on death as a result of bleeding within cate-
gories of baseline risk and provide crude risk ratios. We tested
the homogeneity of treatment effect across these between
categories of risk using the c2 test. We used logistic regression
to assess the effects of antifibrinolytics on death as a result of
bleeding and reported treatment effects with odds ratios and
95% confidence interval (CI). First, we tested the homogeneity
of the treatment effect between trials by including an inter-
action term between treatment and trial and reporting the P-
value (model 1, Supplementary file S2). We hypothesised that
the treatment effect does not vary by baseline risk, unlike time
to treatment for which treatment delay reduces the treatment
benefit.1 To verify the homogeneity of the effect of baseline
risk on treatment effect by time to treatment, we performed a
second model with a triple interaction between the terms for
baseline risk, the treatment group, and the time to treatment
(model 2, Supplementary file S2). Once the homogeneity of the
678 - Ageron et al.treatment effect with baseline risk and time to treatment was
verified, we ran a third model to assess the homogeneity be-
tween the treatment effect and baseline risk adjusting for trial
and time to treatment (model 3, Supplementary file S2). We
reported the P-value for the interaction term between treat-
ment effect and baseline risk and plotted the treatment effects
with odds ratios and 95% CI according to baseline risk.Missing values
There were no missing outcome data, but there were missing
values for some predictor variables. In order to estimate
baseline risks on the full dataset, we replaced missing pre-
dictors using multiple imputation with 20 imputed datasets
and adjustment of the imputation model for death as a result
of bleeding, age, systolic BP, ventilatory frequency, and Glas-
gow outcome scale. 
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Fig 1. Study selection. TXA, tranexamic acid.Results
Figure 1 shows the number of records identified and the rea-
sons for exclusions. We found five completed14e18 and 10
ongoing trials19e28 (Supplementary file S3). All trials used tra-
nexamic acid. Three trials met our inclusion criteria. The
CRASH-2 and WOMAN trials received ethics committee
approval from the London School of Hygiene and Tropical
Medicine, UK and the ethics committees of all participating
hospitals. The CRASH-2 trial included 20 211 trauma patients
and assessed the effects of tranexamic acid on death and
vascular occlusive events. Data from the CRASH-2 trial are
available via freeBIRD (free bank of injury and emergency
research data), hosted by the Clinical Trial Unit (CTU) of the
London School of Hygiene and Tropical Medicine (https://ctu-
app.lshtm.ac.uk/freebird). The WOMAN trial assessed the ef-
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Effect of tranexamic acid - 679060 women with postpartum haemorrhage. The TICH-2 trial
assessed the effect of tranexamic acid on death and de-
pendency in non-traumatic intracerebral haemorrhage.
Exsanguination does not normally occur in adults with cere-
bral haemorrhage. Death usually arises as a result of cerebral
injuries and high ICP. The TICH-2 trial was excluded from
analysis as it was not possible to collect the primary outcome
death as a result of bleeding. Included trials had a low risk of
bias in all domains (Supplementary file S4).
We obtained individual patient data for 28 333 participants
randomised within 3 h of the bleeding onset: 13 485 from the
CRASH-2 trial and 14 848 from the WOMAN trial (Table 1). Of
these, 14 270 participants received tranexamic acid and 14 067
received placebo. The baseline risk predictors for both models
are detailed in the Supplementary file S5. The pooled
discrimination of the prognostic models was good; C-
statistic¼0.88, 95% CI (0.87e0.89). The predicted risk was
similar to the observed risk in the placebo group (ratio pre-
dicted/observed risk¼1.00; 95% CI (0.92e1.07)) (Supplementary
file S6). The baseline riskwas higher in trauma patients than in
women with postpartum haemorrhage. Most patients had a
baseline risk under 5% (Fig. 2). Deaths as a result of bleeding
occurred in all baseline risk categories with almost the same
number of deaths as a result of bleeding. We reported 240 (1%),
202 (8%), 232 (14%), and 357 (30%) deaths in the low-, inter-
mediate-, high-, and very high-risk categories, respectively.
Deaths as a result of bleeding occurred in all categories of
blood loss among women with postpartum haemorrhage
(Supplementary file S7). The effect of tranexamic acid did not
vary between trials (model 1: P¼0.82). We found noTable 1 Baseline characteristics of patients in participating trials.
CRASH-2 trial
(n¼13 485)
Predicted baseline risk, n (%)
0e5 9063 (67.2)
6e10 2011 (14.9)
11e20 1373 (10.2)
>20 1038 (7.7)
Missing 0 (0.0)
Mean baseline risk (SD) 6.9 (9.5)
Median baseline risk (IQR) 3.3 (1.4e7.9)
Age (yr), n (%)
<25 3840 (28.5)
25e29 2400 (17.8)
30e34 1792 (13.3)
35 5453 (40.4)
Missing 0 (0.0)
Mean age (SD) 34.1 (14.0)
Median age (IQR) 30 (24e42)
Systolic BP (mm Hg), n (%)
<75 2074 (15.7)
75e89 2360 (17.8)
90 8813 (66.5)
Missing 238 (1.8)
Mean systolic BP (SD) 96.6 (25.3)
Median systolic BP (IQR) 90 (80e110)
Time to treatment (h), n (%)
1 7452 (55.3)
1e3 6033 (44.7)
Missing 0 (0.0%)
Mean time to treatment (SD) 1.5 (0.8)
Median time to treatment (IQR) 1 (1e2)
IQR, inter-quartile range; SD, standard deviation.heterogeneity in the interaction between treatment effect,
baseline risk, and time to treatment (model 2: P¼0.62 for the
triple interaction). We did not find any significant interaction
between the effect of tranexamic acid on death as a result of
bleeding and baseline risk (model 3: P¼0.51). Figure 3 shows
crude risk ratios by categories of baseline risk. The treatment
effect did not vary by baseline risk (Fig. 4). The risk of vascular
occlusive events was similar according to baseline risk cate-
gories (Table 2). There was no increase in fatal and non-fatal
occlusive events with tranexamic acid in any of the baseline
risk categories (Supplementary file S8).Discussion
Main findings
Our results show that many deaths from bleeding are in pa-
tients at low or intermediate risk and that the mortality
reduction from tranexamic acid does not vary by baseline
risk. We found no evidence of any increase in vascular
occlusive events in any of the risk categories. Our study has
important strengths and some limitations. First, we selected
only randomised trials with more than 1000 patients to
reduce selection bias. Small trials contribute very little evi-
dence but could increase the risk of selection bias.29 Second,
we used a rigorous method to develop prognostic models to
predict baseline risk.30 Specifically, baseline risk was esti-
mated using the entire dataset and not just the placebo
group. By increasing the sample size and constraining the
treatment effect in the regression equation, it improves bothWoman trial
(n¼14 848)
Total
(n¼28 333)
13 945 (93.9) 23 008 (81.2)
481 (3.2) 2492 (8.8)
262 (1.8) 1635 (5.8)
160 (1.1) 1198 (4.2)
0 (0.0) 0 (0.0)
1.6 (4.4) 4.1 (7.7)
0.4 (0.1e1.3) 1.3 (0.3e4.2)
3973 (26.8) 7813 (27.6)
4590 (30.9) 6990 (24.7)
3802 (25.6) 5594 (19.8)
2478 (16.7) 7931 (28.0)
5 (0.0) 5 (0.0)
28.4 (5.7) 31.1 (10.9)
28 (24e32) 29 (24e35)
1011 (6.8) 3085 (11.0)
1563 (10.5) 3923 (14.0)
12 269 (82.7) 21 082 (75.1)
5 (0.0) 243 (0.9)
101.5 (21.4) 99.2 (23.5)
100 (90e110) 100 (90e110)
9220 (62.1) 16 672 (58.8)
5628 (37.9) 11 661 (41.2)
0 (0.0%) 0 (0.0%)
1.0 (0.8) 1.3 (0.8)
0.7 (0.4e1.5) 1 (0.5e2)
Fig 2. Number of patients and number of deaths according to baseline risk.
Fig 3. Effect of tranexamic acid on death as a result of bleeding by baseline risk. CI, confidence interval.
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Fig 4. Effect of baseline risk on treatment benefit. CI, confidence
interval.
Effect of tranexamic acid - 681the precision of prediction and the calibration.31 Third, we
performed logistic regression with baseline risk as a contin-
uous variable since an oneoff step function is biologically
implausible. There was no interaction between treatment
effect, trial, and time to treatment. Even though we restricted
our analyses to patients treated within 3 h of bleeding onset,
as recommended in clinical practice, we included trial and
time to treatment in the model to avoid any residual con-
founding. Fourth, there were no missing outcome data and
very few missing data for predictors of baseline risk (<1%).
Nevertheless, we performed multiple imputation and used
the whole dataset for analysis. We cannot exclude some
measurement error in the predictors used to estimate the
baseline risk and this could lead to regression dilution bias
and over- or under-prediction in some patients.32 Misclassi-
fication of death as a result of bleeding is also possible, as
death from thrombotic disseminated intravascular coagula-
tion could be confused with death from bleeding. We cannot
exclude some misclassification as a result of optimism of the
model affecting calibration. We are reassured that optimismTable 2 Vascular occlusive events by treatment allocation according
Baseline risk, n (%) 0e5% 6e10%
Tranexamic
acid
N¼11 612
Placebo
N¼11 396
Tranexamic
acid
N¼1245
Pla
N
Any vascular
occlusive events
64 (0.6) 65 (0.6) 17 (1.4) 22 (
Fatal occlusive events 16 (0.1) 15 (0.1) 6 (0.5) 4 (0
Myocardial infarction* 8 (0.1) 14 (0.1) 3 (0.2) 7 (0
Stroke* 19 (0.2) 14 (0.1) 3 (0.2) 6 (0
Pulmonary embolism* 28 (0.2) 23 (0.2) 6 (0.5) 8 (0
Deep vein thrombosis* 12 (0.1) 19 (0.2) 7 (0.6) 2 (0
* Includes both fatal and non-fatal events.was low in the model developed for trauma and the selection
of a limited number of predictors limits overfitting.10 11
Finally, the large sample size with more than 28 000 patients
with acute bleeding treated within 3 h of onset gives precise
results. However, estimates of the effects on adverse events
are much less precise. The study included data from 38
countries across several continents and so the results should
be widely generalisable to patients presenting to hospitals
with postpartum haemorrhage and to trauma patients with,
or at risk of, significant haemorrhage.Implications of the study
The main clinical implication of these results is that tra-
nexamic acid treatment should be considered as an early
preventive measure rather than a treatment for severe
coagulopathic bleeding. Because of the large number of pa-
tients in the low- and intermediate-risk groups, these
groups contribute a large number of bleeding deaths.
Indeed, about one-quarter of deaths from bleeding occurred
in patients who initially appeared to have a low risk of
death. Early identification of bleeding can be challenging,
especially in trauma. Patients without obvious bleeding
sometimes have concealed bleeding and can suddenly
deteriorate. Although early identification of bleeding by a CT
scan or FAST (Focused Assement with Sonography for
Trauma) vel is a priority, a definitive diagnosis can take up
to 1 h, even in the best trauma systems. Hence, many major
trauma patients without clinically apparent bleeding will
not receive tranexamic acid soon enough unless early
treatment is given to all major trauma patients whatever
their apparent risk. Major trauma is usually defined as an
injury or a combination of injuries that are potentially life-
threatening or could lead to long-term disability. Because
the full extent of the patient’s injuries is unknown at initial
assessment, trauma team activation criteria represent a
pragmatic alternative definition of major trauma in the
prehospital setting. As for obstetric bleeding, WHO guide-
lines recommend tranexamic acid in addition to standard
care for all women with clinically diagnosed postpartum
haemorrhage. However, if ‘in addition to’ is taken to mean
that tranexamic acid should be given after standard care has
been found to be insufficient to stop the bleeding, this will
result in unnecessary treatment delay. Instead, we believeto baseline risk.
11e20% >20% P-value
cebo
¼1247
Tranexamic
acid
N¼853
Placebo
N¼782
Tranexamic
acid
N¼560
Placebo
N¼638
1.8) 23 (2.7) 38 (4.9) 14 (2.7) 27 (4.2) 0.255
.3) 4 (0.5) 14 (1.8) 1 (0.2) 7 (1.1) 0.058
.6) 6 (0.7) 13 (1.7) 7 (1.3) 12 (1.9) 0.909
.5) 6 (0.7) 15 (1.9) 4 (0.7) 7 (1.1) 0.152
.6) 14 (1.6) 16 (2.1) 6 (1.1) 9 (1.4) 0.739
.2) 6 (0.7) 4 (0.5) 3 (0.5) 5 (0.8) 0.214
682 - Ageron et al.that early tranexamic acid treatment should be considered
integral to standard care.Future studies
We found 13 ongoing trials of antifibrinolytic drugs in acute
severe bleeding. Three of these could provide additional data
on the treatment effect by baseline risk in extracranial
bleeding. However, these ongoing trials are small and their
inclusion is very unlikely to change our conclusions. However,
additional trials could increase the power to detect adverse
effects. Further individual patient level data meta-analyses
that consider vascular occlusive events are needed.Conclusions
Tranexamic acid appears to be safe and effective regardless
of the baseline risk for patients treated within 3 h since
injury. Because many deaths are in patients at low and in-
termediate risk, tranexamic acid use should not be restricted
to the most severely injured or bleeding patients. As tra-
nexamic acid is safe, it should be considered as an early
preventive measure rather than a treatment for severe coa-
gulopathic bleeding.Authors’ contributions
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